ADMA Biologics: MACD and KDJ Death Crosses Signal Downward Trend

ADMA Biologics's 15-minute chart has triggered a MACD Death Cross and a KDJ Death Cross, as of September 30, 2025 at 10:30. This indicates a potential for the stock price to continue declining, with a shift in momentum towards the downside and a potential for further decreases.

Adma Biologics (ADMA) has experienced a notable decline in its stock price, with the 15-minute chart triggering both a MACD Death Cross and a KDJ Death Cross as of September 30, 2025, at 10:30. These technical indicators suggest a potential continuation of the downward trend, indicating a shift in momentum towards the downside and a possible further decrease in the stock price.

The MACD (Moving Average Convergence Divergence) Death Cross occurs when the MACD line crosses below the signal line, signaling a potential reversal in the trend. Similarly, the KDJ (Kaufman Adaptive Moving Average) Death Cross indicates a bearish signal when the K line crosses below the D line. Both of these crosses suggest a potential for a prolonged downward movement in ADMA's stock price.

Heading into today, ADMA's stock had lost 9.22% over the past month, lagging behind the Medical sector's loss of 0.7% and the S&P 500's gain of 2.74%. The company is expected to post an EPS of $0.16 for the upcoming quarter, representing a 6.67% growth compared to the same period last year. Quarterly revenue is projected to reach $130.1 million, up 8.56% from the year-ago period Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

Analysts and investors are closely monitoring ADMA's performance, particularly in light of recent changes in analyst estimates. These revisions highlight the dynamic nature of near-term business trends and provide insight into the company's future prospects. The Zacks Rank system, which considers these estimate changes, currently rates ADMA as a #3 (Hold), indicating a neutral outlook Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

Investors should also consider ADMA's current valuation metrics, such as its Forward P/E ratio of 27.47, which is relatively high compared to the industry average of 19.43. The Medical - Biomedical and Genetics industry, of which ADMA is a part, ranks in the top 36% of all industries, according to the Zacks Industry Rank Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

In conclusion, the technical indicators suggest a potential downward trend for ADMA's stock price. Investors should closely monitor the company's earnings disclosure and valuation metrics to make informed decisions. For the latest updates and stock-moving metrics, visit Zacks.com Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].